🔗 Share this article

While the US continues making historic revisions to its immunization guidelines, a particular individual appears in a surprising turn: Høeg, a US-based physician and epidemiologist who rose to prominence by questioning coronavirus vaccines during the pandemic and has zeroed in on alleged deaths following Covid immunization in her recent time at the Food and Drug Administration.

Scheduled Overhauls to Pediatric Vaccine Program

Public health authorities were set to announce radical changes to the pediatric vaccine schedule recently, bringing the US with Denmark’s immunization schedule, sources say – a substantial departure that would put the US at odds with many the global community with little proof for benefit. The announcement has been delayed until the coming year.

Rather than the director of the vaccine center, Tracy Beth Høeg is set to address the audience at the event. She was recently named acting director of the FDA’s CDER, the fifth individual to run the office this calendar year.

A Shift at the Agency

This interim role may indicate a tighter collaboration between the pharmaceutical and biologics divisions as Dr. Høeg and Dr. Prasad strengthen their influence at the regulatory agency – and it signals a greater focus upon reevaluating already-approved vaccines at the FDA.

Høeg has repeatedly called for discontinuing certain childhood shot schedules in the US to become more like Denmark's approach, a society with nationalized medicine and a citizenry roughly the population of the state of Wisconsin.

In her initial comments, she has kept her attention on vaccines – traditionally the domain of Dr. Prasad, head of the FDA’s CBER – instead of drug regulation.

Questions Over Qualifications

Høeg has no obvious track record in medication creation, approval processes or leadership, which has been customary for former heads of the CBER. She has served at the FDA as a senior adviser to the commissioner and CBER since March.

“She appears not to have the necessary background” for overseeing the pharmaceutical oversight division, stated Dr. Jonathan Howard. “She lacks experience running a clinical trial. She lacks experience in running a large organization. She lacks background in drug approvals.”

Previous heads of CBER would “be deeply familiar with laws and regulations and the underlying principles of medication creation”, noted a former acting FDA commissioner. “Frankly, she lacks the sort of resume that previous people who ran CBER have had.”

The drug center has an enormous range of responsibilities at the FDA, the former commissioner emphasized.

“Everybody just zeroes in on the novel medication approvals, but the generic drug division approves a multitude of generic drugs. There is also a biologic copycat branch, non-prescription drug unit and so forth, and each of these have to be looked after,” Woodcock noted. “The thing you overlook, that is precisely what that I always told people is going to bite you.”

Furthermore, a significant management element to the role, which manages more than 5,000 employees. “It’s a enormous administrative position, if you perform it correctly,” the former official concluded.

Agency Reaction and Controversial Policies

In response to questions about Dr. Høeg's fitness for the role and whether this appointment represents more teamwork among agency officials on immunizations, a press secretary responded that the “concerns rely on inaccurate assumptions”.

“Her experience aligns with the responsibilities of her role,” the official stated, citing the period Høeg spent counseling the agency head on “drug safety and oversight research, including computerized risk analysis and shot safety tracking”.

In her interim role, Høeg inherits the agency head's controversial expedited review system, a disputed one-day medication authorization process that allegedly troubled her former heads. “By what process are these therapies being selected for this voucher program? Who makes the decisions?” Dr. Howard asked. “There is a lot of secrecy going on at the regulatory body right now.”

In general, he stated, “the FDA looks to be trending towards laxer rules of most medications, with the exception of shots.”

Public History on Vaccines

Concerning vaccines, Dr. Høeg has a more documented, if troubling, history, Howard observe. She published a study using unverified public submissions to determine the incidence of heart inflammation following COVID-19 immunization. She consulted for the Florida top health official Dr. Joseph Ladapo, who allegedly have modified findings to indicate Covid vaccines are riskier than they are.

Included in her “desired changes” for the new federal leadership included revising regulations for recently developed shots and ending “non-essential” vaccines, she remarked following the vote on a online show. At the agency, Høeg has reportedly floated the idea of excluding young men from receiving COVID-19 vaccines.

“She’s an thorough true believer who commences with her conclusions and reverse-engineers to fit the evidence in a highly deceptive, fraudulent fashion,” Howard said.

Taking Control and a “Revenge Tour”

Dr. Høeg became part of other contrarians, {like|